The Subjective Effects of Psychedelics May Not Be Necessary for Their Enduring Therapeutic Effects
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Psychedelics represent one of the most promising classes of experimental medicines for the treatment of neuropsychiatric disorders due to their ability to promote neural plasticity and produce both rapid and sustained therapeutic effects following a single administration. Conventional wisdom holds that peak mystical experiences induced by psychedelics are a critical component of their therapeutic mechanisms of action, though evidence supporting that claim is largely correlational. Here, I present data suggesting that the subjective effects induced by psychedelics may not be necessary to produce long-lasting changes in mood and behavior. Understanding the role of subjective effects in the therapeutic mechanisms of psychedelics will have important implications for both basic neuroscience and for increasing patient access to the next generation of medicines developed as a result of psychedelic research.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Whiteford, H. A., Degenhardt, L., Rehm, J., Baxter, A. J., Ferrari, A. J., Erskine, H. E., Charlson, F. J., Norman, R. E., Flaxman, A. D., Johns, N., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61611-6 · Cited by 6,006
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201
Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698
NMDAR inhibition-independent antidepressant actions of ketamine metabolites
Zanos, P., Moaddel, R., Morris, P. J., Georgiou, P., Fischell, J., Elmer, G. I., Alkondon, M., Yuan, P., Pribut, H. J., Singh, N. S., et al. (2016) · Nature · doi:10.1038/nature17998 · Cited by 1,609
New approaches to antidepressant drug discovery: beyond monoamines
Berton, O., & Nestler, E. J. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1846 · Cited by 1,589
Psychedelics promote structural and functional neural plasticity
Ly, C., Greb, A. C., Cameron, L. P., Wong, J. M., Barragan, E. V., Wilson, P. C., Burbach, K. F., Soltanzadeh Zarandi, S., Sood, A., Paddy, M. R., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.022 · Cited by 1,207
Self-citationPsilocybin-assisted treatment for alcohol dependence: A proof-of-concept study
Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A., Wilcox, C. E., Barbosa, P., & Strassman, R. J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114565144 · Cited by 1,151
Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action
Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F. I., Bäbler, A., Vogel, H., & Hell, D. (1998) · NeuroReport · doi:10.1097/00001756-199812010-00024 · Cited by 1,018
Roseman, L., Nutt, D. J., & Carhart-Harris, R. L. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00974 · Cited by 808
Cited by
Items 101–200 of 344
Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo
Shao, L.-X., Liao, C., Gregg, I., Davoudian, P. A., Savalia, N. K., Delagarza, K., & Kwan, A. C. (2021) · doi:10.1101/2021.02.17.431629 · Cited by 628
“It has long been recognized that these compounds may have therapeutic potential for neuropsychiatric disorders including depression, obsessive-compulsive disorder, and addiction (Nichols, 2016; Vollenweider and Preller, 2020).”
Kiraga, M. K., Kuypers, K. P. C., Uthaug, M. V., Ramaekers, J. G., & Mason, N. L. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.883869 · Cited by 26
“That said, it has yet to be systematically assessed whether such a “peak” experience is necessary for long-term outcomes (95), or whether the subjective experiences elicited by psychedelic substances are merely epiphenomena of the underlying neurobiological mechanisms, the latter which are conveying any beneficial eff…”
BackgroundAyahuasca for the Treatment of Depression
Palhano-Fontes, F., Soares, B. L., Coelho, N. L. G., Arcoverde, E., & de Araújo, D. B. (2021) · Current topics in behavioral neurosciences · doi:10.1007/7854_2021_277 · Cited by 35
Nikolaidis, A., Lancelotta, R., Gukasyan, N., Griffiths, R. R., Barrett, F. S., & Davis, A. K. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.12.042 · Cited by 28
Language as a Window Into the Altered State of Consciousness Elicited by Psychedelic Drugs
Tagliazucchi, E. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.812227 · Cited by 26
Psychedelic Mystical Experience: A New Agenda for Theology
Cole‐Turner, R. (2022) · Religions · doi:10.3390/rel13050385 · Cited by 25
Psychedelic Science of Spirituality and Religion: An Attachment-Informed Agenda Proposal
Cherniak, A. D., Brulin, J. G., Mikulincer, M., Östlind, S., Carhart-Harris, R. L., & Granqvist, P. (2022) · International Journal for the Psychology of Religion · doi:10.1080/10508619.2022.2148061 · Cited by 31
“Yet, some scholars argue that psychedelic-induced RSMEs are epiphenomenal byproducts of the neurobiological mechanisms that may explain psychedelics’ therapeutic effects (Olson, 2021).”
Bedside to bench: the outlook for psychedelic research
Acero, V. P., Cribas, E. S., Browne, K. D., Rivellini, O. M., Burrell, J. C., O’Donnell, J. C., Das, S., & Cullen, D. K. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1240295 · Cited by 28
“…these disruptions of network connectivity appear to mediate the typical psychedelic experience, it is still unclear to which extent these disruptions, as opposed to individual psychological experience, facilitate the alleviation of psychological suffering (Olson, 2021; Yaden and Grif fi ths, 2021).”
BackgroundMolecular and Medical Aspects of Psychedelics
Wojtas, A., & Gołembiowska, K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms25010241 · Cited by 27
“The development of non-hallucinogenic compounds such as analogs of 5-MeO-DMT, 6-MeO-isoDMT or tabernanthalog (TBG), which exhibit reduced hallucinogenic potential while retaining psychoplastogenic potency, may greatly improve the accessibility of therapy with psychedelics [172].”
BackgroundNogueira, M., Golbert, D. C. F., de Menezes, R. S. T., de Almeida, R. N., Coelho, N. L. G., Siroky, A. N., Lima, T. Z., Maia, H., Leão, K. E., & Leão, R. N. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02655-w · Cited by 26
Psychedelic Epistemology: William James and the “Noetic Quality” of Mystical Experience
Cole‐Turner, R. (2021) · Religions · doi:10.3390/rel12121058 · Cited by 24
The illusion of knowledge in the emerging field of psychedelic research
Oña, G., Kohek, M., & Bouso, J. C. (2022) · New Ideas in Psychology · doi:10.1016/j.newideapsych.2022.100967 · Cited by 28
Thal, S. B., Wieberneit, M., Sharbanee, J. M., Skeffington, P., Baker, P., Bruno, R., Wenge, T., & Bright, S. J. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221127954 · Cited by 26
“Nevertheless, there is an ongoing debate regarding the necessity of the subjective effects of psychedelics for their enduring therapeutic efficacy (Olson, 2021; Yaden and Griffiths, 2021).”
BackgroundPsychedelic innovations and the crisis of psychopharmacology
Langlitz, N. (2022) · BioSocieties · doi:10.1057/s41292-022-00294-4 · Cited by 28
“This camp acknowledged Griffiths’ finding that clinical improvements correlated with the intensity of mystical-type experiences but pointed out that correlation did not prove causation (Olson 2021).”
Cooper, T., Seigler, M. D., & Stahl, S. M. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231158891 · Cited by 23
Dworkin, R. H., Anderson, B. T., Andrews, N., Edwards, R. R., Grob, C. S., Ross, S., Satterthwaite, T. D., & Strain, E. C. (2022) · Journal of Pain · doi:10.1016/j.jpain.2022.05.003 · Cited by 27
Psychedelics align brain activity with context
Stoliker, D., Novelli, L., Khajehnejad, M. A., Biabani, M., Greaves, M. D., Barta, T., Williams, M., Chopra, S., Bazin, O., Simonsson, O., et al. (2026) · Nature · doi:10.1038/s41586-026-10910-z · Cited by 26
“The observed relationship between subjective experience and psychological shifts provides empirical context for ongoing debates about the necessity of the psychedelic experience for clinical efficacy (Yaden and Griffiths, 2020; Olson, 2020; Goodwin et al., 2025).”
Moreton, S. G., Arena, A. F. A., Foy, Y., & Menzies, R. E. (2023) · Death Studies · doi:10.1080/07481187.2023.2169848 · Cited by 23
“Although research is still unpacking why psychedelic experiences might improve subjective well-being, Yaden and Griffiths (2021) review substantial evidence suggesting that the subjective psychedelic experience may be key to their benefits (although see Olson, 2020).”
BackgroundSpirituality as a Therapeutic Approach for Severe Mental Illness: Insights from Neural Networks
Knegtering, H., Bruggeman, R., & Spoelstra, S. K. (2024) · Religions · doi:10.3390/rel15040489 · Cited by 25
Rodríguez‐Cano, B. J., Kohek, M., Oña, G., Alcázar‐Córcoles, M. Á., SANTOS, R. G. D., Hallak, J. E. C., & Bouso, J. C. (2022) · Drug and Alcohol Review · doi:10.1111/dar.13587 · Cited by 20
How Do Psychedelics Reduce Fear of Death?
Letheby, C. (2024) · Neuroethics · doi:10.1007/s12152-024-09564-3 · Cited by 20
“Some have suggested that the therapeutic effects of psychedelic administration might be caused mainly by non-experiential, purely neuro-biological effects of the drugs [30].”
Walther, R. F. E., & van Schie, H. T. (2024) · Psychoactives · doi:10.3390/psychoactives3030026 · Cited by 22
“There is, notably, an ongoing debate regarding the necessity of the subjective experience for long-lasting clinical outcomes in particular for therapy assisted by psychedelic substances [7,83,84].”
Artru, E., & Rabeyron, T. (2021) · L Évolution Psychiatrique · doi:10.1016/j.evopsy.2021.03.013 · Cited by 22
Rediscovering Psilocybin as an Antidepressive Treatment Strategy
Zeiss, R., Gahr, M., & Graf, H. (2021) · Pharmaceuticals · doi:10.3390/ph14100985 · Cited by 32
“argue that the psychedelic effect may represent a marker for the responsiveness of the 5-HT2A receptor, and thus for neuroplasticity and psychoplastogenic effects [69].”
BackgroundNewton, K., & Moreton, S. G. (2022) · Ecopsychology · doi:10.1089/eco.2022.0044 · Cited by 22
“Emerging research suggests that it may be the acute psychological experiences that psychedelics induce, rather than solely their physiological effects, that may be crucial in understanding the enduring positive outcomes (Olson, 2020; Yaden & Griffiths, 2020).”
Psychedelics and disorders of consciousness: the current landscape and the path forward
Cardone, P., Alnagger, N., Annen, J., Bicego, A., Gosseries, O., & Martial, C. (2024) · Neuroscience of Consciousness · doi:10.1093/nc/niae025 · Cited by 19
“…such substance would have huge implications on the nature of the relationship between complexity and consciousness, as well as understanding if clinical changes could be attributed to the subjective experience (Yaden and Griffiths 2020) or to its underlying neurophysiological effects (Olson 2021).”
BackgroundMoreton, S. G., Burden-Hill, A., & Menzies, R. E. (2022) · Clinical Psychologist · doi:10.1080/13284207.2022.2086793 · Cited by 19
Psychedelics, entactogens and psychoplastogens for depression and related disorders
Hoyer, D. (2025) · British Journal of Pharmacology · doi:10.1111/bph.70088 · Cited by 18
“…and although the answer can only come from clinical studies, there are significant efforts to develop psilocybin-and other NCEs lacking the “ psychedelic experience ” (Cameron & Olson, 2022; Hashimoto, 2024; Madsen et al., 2021; Olson, 2021; Siva et al., 2024; Sondergaard et al., 2022).”
Liu, G., Ma, L., Qu, Y., Wan, X., Xu, D., Zhao, M., Murayama, R., & Hashimoto, K. (2023) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2023.173659 · Cited by 19
A qualitative analysis of the psychedelic mushroom come-up and come-down
Brouwer, A., Brown, J. K., Erowid, E., Erowid, F., Thyssen, S., Raison, C. L., & Carhart-Harris, R. L. (2025) · npj Mental Health Research · doi:10.1038/s44184-024-00095-6 · Cited by 19
“Evidenceisstrongthattheacutesubjectiveeffects ofpsychedelicsplayaroleinmoderatingoutcomes 1 – 3 , while others argue, mostly based on rodent research, that conscious experience may be secondary or peripheral to the therapeutic effects of these agents 4 .”
The evolution of the psychedelic revolution
Cameron, L. P., & Olson, D. E. (2021) · Neuropsychopharmacology · doi:10.1038/s41386-021-01150-y · Cited by 20
“While the role of mystical-type experiences in the therapeutic properties of first-generation psychoplastogens is the subject of intense debate, mounting evidence suggests that beneficial psychoplastogenic effects can be achieved without inducing hallucinations [2].”
BackgroundSelf-citationHultgren, J., Hafsteinsson, M. H., & Brulin, J. G. (2025) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2025.07.020 · Cited by 17
Harnessing Pharmacogenomics in Clinical Research on Psychedelic‐Assisted Therapy
Halman, A., Conyers, R. K., Moore, C., Khatri, D., Sarris, J. J., & Perkins, D. (2024) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3459 · Cited by 19
“17 For drugs in general, several factors are known to affect efficacy, one of these being genetics, which can alter both the pharmacokinetics and pharmacodynamics of a drug.”
Berkovitch, L., Fauvel, B., Preller, K. H., & Gaillard, R. (2025) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2025.106239 · Cited by 17
Concomitant use of antidepressants and classic psychedelics: A scoping review
Tap, S. C., Thomas, K. L. H., Páleníček, T., Stenbæk, D. S., Oliveira-Maia, A. J., van Dalfsen, J. H., & Schoevers, R. A. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251368360 · Cited by 16
“Conversely, it is argued that psychedelics may also exert therapeutic effects in the absence of acute subjective effects and are instead mediated by neurobiological mechanisms (Olson, 2020, 2022).”
Postpartum depression: A role for psychedelics?
Jairaj, C., & Rucker, J. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221093793 · Cited by 17
“Mystical-type experiences are associated with enduring improvements in depression and anxiety outcome measures in psilocybin trials and are thought to mediate these positive effects (Griffiths et al., 2016; Ross et al., 2016), although contrasting views also exist (Olson, 2020).”
BackgroundAtiq, M. A., Baker, M. R., Voort, J. L. V., Vargas, M. V., & Choi, D. (2024) · Psychopharmacology · doi:10.1007/s00213-024-06599-5 · Cited by 18
“(Aday et al. 2022; Muthukumaraswamy et al. 2022, 2021).”
InfluentialSix-Step Synthesis of (±)-Lysergic Acid
Knight, B. J., Harbit, R. C., & Smith, J. M. (2023) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.2c02564 · Cited by 16
μ-opioid receptor agonists and psychedelics: pharmacological opportunities and challenges
Salinsky, L. M., Merritt, C. R., Zamora, J. C., Giacomini, J. L., Anastasio, N. C., & Cunningham, K. A. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1239159 · Cited by 16
“…al., 2019; Rasmussen et al., 2019; Higgins et al., 2020), there are on-target side effects such as hypophagia and anhedonia (Lam et al., 2008; Yamamoto et al., 2017) as is the case for 5-HT 2A R agonists (hallucinations) that may limit their clinical practicality (Shalit et al., 2019; Olson, 2021).”
BackgroundHuman behavioral pharmacology of psychedelics
Strickland, J. C., & Johnson, M. W. (2022) · Advances in pharmacology · doi:10.1016/bs.apha.2021.10.003 · Cited by 16
Neuropsychopharmacology of hallucinogenic and non‐hallucinogenic 5‐HT 2A receptor agonists
Sharp, T., & Ippolito, A. (2025) · British Journal of Pharmacology · doi:10.1111/bph.70050 · Cited by 17
“Although in the case of depression the magnitude of the subjective experience is reported to correlate with clinical outcome, the causal link with the therapeutic effect is not proven and much discussed in recent commentaries (Olson, 2021; Yaden & Griffiths, 2021).”
Jastrzębski, M. K., Wójcik, P., Grudzińska, A., Andreozzi, G., Vetrò, T., Asim, A., Mudgal, A., Czapiński, J., Wróbel, T. M., Bartuzi, D., et al. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.07.002 · Cited by 15
Sakai, K., Bradley, E., Zamaria, J. A., Agin-Liebes, G., Kelley, D. P., Fish, A., Martini, V., Ferris, M. C., Morton, E. E., Michalak, E. E., et al. (2024) · Psychopharmacology · doi:10.1007/s00213-024-06585-x · Cited by 17
“Evidence regarding the relationship between intensity and quality of the experience and subsequent benefit is mixed (Anderson et al. 2020; Griffiths et al. 2006, 2016; Olson 2020; Rotz et al. 2023).”
Psilocybin for Depression: From Credibility to Feasibility, What’s Missing?
Munafò, A., Arillotta, D., Mannaioni, G., Schifano, F., Bernardini, R., & Cantarella, G. (2022) · Pharmaceuticals · doi:10.3390/ph16010068 · Cited by 15
“Theoretically, an active placebo that mimics psychedelic effects without providing therapeutic benefit might appear appropriate for this purpose, although one would argue that it may well be the “mystical state” itself that may drive the beneficial effects [31,32,82].”
BackgroundPsychedelics as a potential treatment for tobacco use disorder: a systematic review
Spoelstra, S. K., Schoevers, R. A., Venema, S. D., & Knegtering, H. (2024) · Discover Mental Health · doi:10.1007/s44192-024-00095-0 · Cited by 14
“Although some researchers believe that psychedelic experiences while using psychedelics predict therapeutic effects in managing addiction, others tend to regard these experiences just as an unnecessary side-effect [23, 25–27].”
BackgroundEthical Aspects of Psychedelic-Assisted Treatments: An Overview
Poppe, C. J., & Repantis, D. (2024) · Current topics in behavioral neurosciences · doi:10.1007/7854_2024_533 · Cited by 14
Schenberg, E. E. (2025) · Pharmacology Research & Perspectives · doi:10.1002/prp2.70097 · Cited by 16
LSD's rapid antidepressant effects are modulated by 5-HT2B receptors
Bouloufa, A., Delcourte, S., Rovera, R., Delannay, T., Duquet, A., Moulédous, L., Dkhissi‐Benyahya, O., Guiard, B. P., & Haddjeri, N. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118348 · Cited by 14
Adebo, M., Bonnet, M., Laouej, O., Defaix, C., McGowan, J. C., Butlen‐Ducuing, F., David, D. J. P., Poupon, E., Tritschler, L., & Gardier, A. M. (2025) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.70038 · Cited by 14
“There are very few clinical studies that have specifically addressed this issue, none of them being double-blind, placebo-controlled clinical trials of psychedelics microdosing [111].”
InfluentialThe Promise of Psychedelic Science
Olson, D. E. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.1c00071 · Cited by 14
Self-citationBarnett (2024) · doi:10.1089/psymed.2023.0010 · Cited by 13
Nicholas, C. R. N., Banks, M. I., Lennertz, R. C., Wenthur, C. J., Krause, B. M., Riedner, B. A., Smith, R., Hutson, P. R., Sauder, C. J., Dunne, J. D., et al. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-03059-8 · Cited by 19
Psilocybin and Hallucinogenic Mushrooms
Fradet, M., Kelly, C. M., Donnelly, A. J., & Suppes, T. M. (2024) · Cambridge University Press eBooks · doi:10.1017/9781009585330.004 · Cited by 13
Drewko, A. J., Habets, R. L. P., & Brunt, T. M. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03169-9 · Cited by 16
“…behind depression [18 – 20], as well as the fi nding that commercially available antidepressants also display some psychoplasto-genic properties [21, 22], there is a great divide over whether the hallucinogenic properties of psychedelics are useful for their therapeutic applications [23, 24].”
van den Berg, M., Magaraggia, I., Schreiber, R., Hillhouse, T. M., & Porter, J. H. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06106-8 · Cited by 13
“2018), it has been hypothesized that the antidepressant effects of psychedelics are, similarly to ketamine, independent from their psychedelic and mystical properties (Olson 2021).”
BackgroundDavid, J., Bouso, J. C., Kohek, M., Oña, G., Tadmor, N., Arnon, T., Dor‐Ziderman, Y., & Berkovich‐Ohana, A. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1287961 · Cited by 14
Weleff, J., Nunes, J. C., Costa, G. P. A., Sofuoglu, M., MacLean, R. R., & Aquino, J. P. D. (2024) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.16045 · Cited by 15
“132,133 There is a suggestion that in both, at least, treatment-resistant depression and tobacco-use disorder, the subjective components and quality of the acute psychedelic experience may be important for therapeutic efficacy, 134 while there remains some preliminary data in OUD this may be the…”
Preclinical models for evaluating psychedelics in the treatment of major depressive disorder
Alexander, L., Anderson, D., Baxter, L., Claydon, M. D. B., Rucker, J., & Robinson, E. S. J. (2024) · British Journal of Pharmacology · doi:10.1111/bph.17370 · Cited by 13
“…in rodent models suggest that non-psychedelic 5-HT 2A receptor agonists induce behavioural effects which may predict antidepressant efficacy suggesting the 5-HT 2A receptor is important but inducing a psychedelic effect may not be necessary (Cameron et al., 2021; Kaplan et al., 2022; Olson, 2021).”
Clinical and preclinical evidence of psilocybin as antidepressant. A narrative review
Erkizia-Santamaría, I., Horrillo, I., Meana, J. J., & Ortega, J. E. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111249 · Cited by 13
“The role of 5HT2AR, main substrate of hallucinogenic effects of classic psychedelics is particularly pertinent regarding their ability to produce long-lasting changes in behaviour (Olson, 2021; Yaden and Griffiths, 2021).”
Cyberdelics: Virtual reality hallucinations modulate cognitive-affective processes
Brizzi, G., Pupillo, C., Rastelli, C., Greco, A., Bernardelli, L., Natale, A. F. D., Pizzoli, S. F. M., Sajno, E., Frisone, F., Lernia, D. D., et al. (2025) · Dialogues in Clinical Neuroscience · doi:10.1080/19585969.2025.2499459 · Cited by 13
“Olson (Olson 2021) cautions that these effects are part of a broader set of mechanisms that include pharmacological and contextual factors. this is reflected in our results, where hVVes, despite enhancing absorption, reduced fluency and moderated the relaxing effects of the relaxation condition.”
Purple, R. J., Gupta, R., Thomas, C. W., Golden, C. T., Palomero‐Gallagher, N., Carhart-Harris, R. L., Froudist‐Walsh, S., & Jones, M. W. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03182-y · Cited by 13
McQueney, A. J., & Garcia, E. J. (2024) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2024.112426 · Cited by 13
de la Fuente Revenga, M., Zhu, B., Guevara, C. A., Naler, L. B., Saunders, J. M., Zhou, Z., Toneatti, R., Sierra, S., Wolstenholme, J. T., Beardsley, P. M., et al. (2021) · doi:10.1101/2021.02.24.432725 · Cited by 11
Assessing potential of psilocybin for depressive disorders
Kozak, Z., Johnson, M. W., & Aaronson, S. T. (2023) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2023.2273493 · Cited by 11
“The extent to which such subjective experiences are necessary for therapeutic benefit is an area of active debate [43].”
BackgroundGonçalves, K. T. D. C., Tavares, V. D. D. O., Barros, M. L. D. M., de Brito, A. J. C., Cavalcanti-Ribeiro, P., Palhano-Fontes, F., Falchi-Carvalho, M., Arcoverde, E., SANTOS, R. G. D., Hallak, J. E. C., et al. (2024) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-024-01925-6 · Cited by 13
“While in the ayahuasca trial for TRD [17], although significant correlations were observed between psychedelic effects and changes in depressive symptoms, it was in a single subscale of the HRS and MEQ [21].”
InfluentialEffects of psychedelics on opioid use disorder: a scoping review of preclinical studies
Pulido-Saavedra, A., Oliva, H. N. P., Prudente, T. P., Kitaneh, R., Nunes, E. J., Fogg, C., Funaro, M. C., Weleff, J., Nia, A. B., & Angarita, G. A. (2025) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-024-05519-2 · Cited by 12
Non-hallucinogenic psychedelics for mood and anxiety disorders: A systematic review
Chen, M. J. Q., Chen-Li, D. C. J., Chisamore, N., Husain, M. I., Vincenzo, J. D. D., Mansur, R. B., Phan, L., Johnson, D. E., McIntyre, R. S., & Rosenblat, J. D. (2025) · Psychiatry Research · doi:10.1016/j.psychres.2025.116532 · Cited by 11
“Therefore, subjective experiences might not be necessary to produce satisfactory therapeutic responses (Olson, 2021; Yaden and Griffiths, 2021).”
The ABCs of psychedelics: a preclinical roadmap for drug discovery
Kwan, A. C., Mantsch, J. R., & McCorvy, J. D. (2025) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2025.07.017 · Cited by 11
da Cruz, R. V. L., Costa, R. B. G. D. M., de Queiroz, G. M., Stojanovic, T., Moulin, T. C., & Leão, R. N. (2026) · Translational Psychiatry · doi:10.1038/s41398-026-03852-7 · Cited by 11
“While some authors argue that the hallucinogenic conscious experience is necessary for enduring clinical bene fi ts [49], others suggest that psychedelics act through downstream molecular and synaptic mechanisms that might be separable from conscious perception [50].”
Knowing and being known: Psychedelic–assisted psychotherapy and the sense of authenticity
Fischman, L. G. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.933495 · Cited by 13
“The twin legacy of this research is both the current enthusiasm, if not craze, to apply these drugs to the treatment of a rapidly expanding list of psychiatric diagnoses, as well as the emergence of voices cautioning against accepting mystical experiences as explanations for biomedical treatments (3, 4).”
BackgroundPsychedelics and the Entropic Brain Beyond the Self
Eyghen, H. V. (2023) · International Journal for the Psychology of Religion · doi:10.1080/10508619.2023.2192078 · Cited by 12
“Microdosing would also have lasting beneficial effects (Olson, 2020).”
BackgroundToward Translatable Biomarkers of Psychedelic-Induced Neuroplasticity
Olson, D. E. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20231054 · Cited by 13
Self-citationGezon, L. L. (2024) · Journal of Psychedelic Studies · doi:10.1556/2054.2024.00381 · Cited by 14
“…subjective effects, such as self-reported mystical-type experiences, produce enduring bene fi cial effects (Brennan & Belser, 2022; Yaden & Grif-fi ths, 2021) or whether the chemical effects are more important than subjective mystical experiences for treating neuropsychiatric diseases (Olson, 2021).”
BackgroundPsychedelic medicine: mechanisms, evidence, and translation to practice
Jacobs, E., Zahid, Z., Hinkle, J. T., Nayak, S. M., & Yaden, D. B. (2026) · BMJ · doi:10.1136/bmj-2024-081723 · Cited by 10
CCNP Innovations in Neuropsychopharmacology Award
Gobbi, G. (2024) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.240037 · Cited by 11
Treatment-Resistant Depression
Hughes, M. E., & Levine, S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95702-1.00065-8 · Cited by 10
Kehler, J., & Lindskov, M. S. T. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251330741 · Cited by 9
Role of endogenous serotonin in psychedelic-like effects of psilocybin in mice
Erkizia-Santamaría, I., Martínez-Álvarez, N., Salinas-Novoa, L., Meana, J. J., & Ortega, J. E. (2025) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaf035 · Cited by 9
“40,41 It is conceivable that certain 5HT2AR agonist drugs lacking psychedelic activity may still induce long-term neuroplastic and therapeutic effects, as suggested by some authors.”
Songs of Life: Psychedelic-Assisted Psychotherapy and Deleuze and Guattari’s ‘Desiring-Production’
Kubala, P. (2023) · Deleuze and Guattari Studies · doi:10.3366/dlgs.2023.0531 · Cited by 9
Immersive exposure to simulated visual hallucinations modulates high-level human cognition
Greco, A., Rastelli, C., Ubaldi, A., & Riva, G. (2025) · Consciousness and Cognition · doi:10.1016/j.concog.2025.103808 · Cited by 9
Critical Period Plasticity as a Framework for Psychedelic-Assisted Psychotherapy
Lepow, L., Morishita, H., & Yehuda, R. (2023) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.23021012 · Cited by 11
Adamczyk, S., Paczyńska, M., Ruban, A., Szczypiński, J., Bola, M., & Orlowski, P. (2025) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2025.2464797 · Cited by 9
“…intensity and quality of the acute ego dissolution experience to the potential of psychedelics to exert a lasting influence on behavior, beliefs, and psychological functioning (Carhart-Harris and Goodwin 2017; Yaden and Griffiths 2020; Stoliker et al. 2022; for an alternative view see Olson 2020).”
García‐Cabrerizo, R., Beruete-Fresnillo, I., Bergas-Cladera, P., & García-Fuster, M. J. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118720 · Cited by 9
User perceptions of long-term costs and benefits of MDMA use: findings from a large online sample
Elsey, J. W. B., Wuestman, V. A. F., & Fieten, A. (2023) · Drugs Education Prevention and Policy · doi:10.1080/09687637.2023.2284643 · Cited by 9
“It is increasingly recognized that drug effects can be understood as operating not only in terms of altered neurochemis-try, but with reference to the subjective experiences this neurochemistry may enable or facilitate (Roseman et al., 2017, though see Olson, 2020).”
Informed Consent in Psychedelic-Assisted Therapy
Bradberry, M. M., Appelbaum, P. S., & Gukasyan, N. (2024) · Current topics in behavioral neurosciences · doi:10.1007/7854_2024_559 · Cited by 8
Exline, J. J., Schutt, W. A., Pait, K. C., & Wilt, J. A. (2022) · International Journal for the Psychology of Religion · doi:10.1080/10508619.2022.2148062 · Cited by 8
“Recent research suggests that psychedelics promote neuritogenesis (Ly et al., 2018), prompting new neural pathways that may contribute to their effectiveness for the treatment of psychiatric conditions (Olson, 2018, 2020).”
BackgroundPsychedelics and neural plasticity
Sumner, R. L., & Łukasiewicz, K. (2023) · BMC Neuroscience · doi:10.1186/s12868-023-00809-0 · Cited by 8
Thuery, G., Sheridan, C., Iusan, P., Brar, G., Ledden, K., Freyne, A., Kelly, J. R., & Harkin, A. (2025) · Acta Neuropsychiatrica · doi:10.1017/neu.2025.10030 · Cited by 8
Navigating the mainstreaming of psychedelics
Labate, B. C., Antunes, H. F., Beachy, J., Sloshower, J., & Cavnar, C. (2025) · Journal of Psychedelic Studies · doi:10.1556/2054.2024.00429 · Cited by 8
Wittenkeller, L. M., Gudelsky, G. A., Winhusen, T. M., & Amato, D. (2025) · British Journal of Pharmacology · doi:10.1111/bph.70181 · Cited by 10
“Consequently, there is a great desire to establish therapeutic effects in the absence of a mystical experience or using new treatments that lack psychedelic effects (Hashimoto, 2024; Olson, 2021), which would avert functional unblinding.”
Impact of psychedelics on craving in addiction: A systematic review
Chapron, S., Bonazzi, G., Lodovico, L. D., de Ternay, J., Landmann, C., Nourredine, M., Salvo, F., Sessa, B., Das, R., Rolland, B., et al. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811241308613 · Cited by 7
“Indeed, among the nine double-blind, placebo-controlled trials using ketamine as an intervention (Dakwar et al., 2014, 2017, 2019, 2020; Das et al., 2019; Grabski et al., 2022; Krupitsky et al., 2002, 2007; Krystal et al., 1998), only five displayed sufficient information allowing meta-analysis…”
InfluentialKim, S., Yang, S., Jung, J., Choi, J., Kang, M., & Joo, J. (2025) · Advanced Science · doi:10.1002/advs.202413786 · Cited by 10
Elf, P., Isham, A., & Leoni, D. (2023) · History of Pharmacy and Pharmaceuticals · doi:10.3368/hopp.65.1.33 · Cited by 9
Psychedelic therapeutics in psychiatric conditions
Harvey, P. D., & Nemeroff, C. B. (2026) · Neuropsychopharmacology · doi:10.1038/s41386-026-02335-z · Cited by 8
Lawrence, D. W., Battista, A. P. D., & Timmermann, C. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2023.2230568 · Cited by 6
“The subjective effects of the psychedelic experience have been previously labeled as “epiphenomenal by-products” (Aqil and Roseman 2023; Olson 2021; Sanders and Zijlmans 2021); however, recent arguments caution against this approach and recommend valuing the phenomenological features in order to…”
Bhatt, K. V., Asuncion, J. D., Alam, A., Zisook, S., & Stahl, S. M. (2025) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2025.07.001 · Cited by 8
da Cruz, L. V. M., Bienemann, B., Palhano-Fontes, F., Tófoli, L. F., de Araújo, D. B., & Mograbi, D. C. (2023) · Scientific Reports · doi:10.1038/s41598-023-44193-5 · Cited by 13
“The integration with subjective aspects of the experience may be particularly relevant considering it has been argued these are necessary for the therapeutic effects of psychedelics 17 , but see 18 .”
Psychedelics for Alcohol Use Disorder: A Narrative Review with Candidate Mechanisms of Action
Miller, E. A., Capone, C., Eaton, E. M., Swift, R. M., & Haass‐Koffler, C. L. (2025) · CNS Drugs · doi:10.1007/s40263-025-01199-z · Cited by 7
“At the same time, other scholars have questioned whether the psychedelic experience is necessary, or whether instead it might represent a epiphenom-enon or biomarker of underlying therapeutic mechanisms that do not inherently rely on the experience [129, 130].”
Disrupting Substance Use Disorder: The Chemistry of Iboga Alkaloids
Hughes, A. J., Hamelink, C. R., & Townsend, S. D. (2024) · European Journal of Organic Chemistry · doi:10.1002/ejoc.202400432 · Cited by 7
Puigseslloses, P., Nadal‐Gratacós, N., Fumàs, B., Modenutti, C. P., Pottie, E., Ortigosa, J., Pablo-Quesada, A., Riera-Colomer, C., Ettcheto, M., Berzosa, X., et al. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03308-2 · Cited by 6
Metadata
- Authors
- Olson, D. E.
- Affiliations
- University of California, Davis (US)
- Corresponding author
- Olson, David E.
- ORCID
- Olson, David E.
- Venue
- ACS Pharmacology & Translational Science
- Publisher
- American Chemical Society (ACS)
- Published
- 2020-12-10
- Volume
- 4
- Issue
- 2
- Pages
- 563-567
- ISSN
- 2575-9108 (ISSN-L)
- PMC
- PMC8033607
- OpenAlex
- W3112904824
- Cited by
- 329
- References
- 36
- Citations by year
- 2026: 43 · 2025: 70 · 2024: 69 · 2023: 55 · 2022: 58 · 2021: 31 · 2020: 2
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- Locations
- ACS Pharmacology & Translational Science (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institutes of Health (R01GM128997)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cognitive Neuroscience › Pain Management and Placebo Effect
- Keywords
- psychedelics, subjective effects, mystical experience, mood, behavior, neuroplasticity, neuropsychiatric disorders, psychedelic medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.